miR-146a-Enriched Mesenchymal Stem Cell-Derived Extracellular Vesicles Prolong Corneal Allograft Survival by...

Area of Science:

• Ophthalmology
• Immunology
• Regenerative Medicine

Background:

• Corneal allograft rejection is a primary cause of graft failure.
• Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) offer potential immunomodulatory strategies for allografts.

Purpose of the Study:

• To investigate if miR-146a-enriched EVs can extend corneal allograft survival.
• To determine the impact of miR-146a-EVs on local and systemic immune responses.

Main Methods:

• Corneal allograft transplantation in mice (C57BL/6 to BALB/c).
• Subconjunctival injection of PBS, miR-NC-EVs, or miR-146a-EVs derived from human umbilical cord MSCs.
• Analysis of local inflammatory markers (IRAK1, TRAF6, TNF-α, Foxp3) via qRT-PCR and systemic cytokines (IFN-γ, IL-17, IL-10, TGF-β) via ELISA.

Main Results:

• miR-146a-EVs significantly reduced clinical rejection scores and improved graft opacity, edema, and neovascularization.
• Corneal tissue analysis revealed miR-146a overexpression, suppressed IRAK1/TRAF6/TNF-α, and increased Foxp3.
• Systemic analysis showed decreased IFN-γ/IL-17 and increased IL-10/TGF-β levels.

Conclusions:

• miR-146a-enriched EVs represent a novel cell-free therapy for prolonging corneal transplant survival.
• This therapy modulates local inflammation and systemic immunity, shifting towards an anti-inflammatory profile.
• miR-146a-EVs offer a targeted approach to prevent transplant rejection.